Skip to main content

The Promise and Challenge of Big Data for Pharma

By December 1, 2016News
pharma-drugs-pixa

pharma-drugs-pixa

The emergence of big data, as well as advancements in data science approaches and technology, is providing pharmaceutical companies with an opportunity to gain novel insights that can enhance and accelerate drug development. It will increasingly help government health agencies, payers, and providers to make decisions about such issues as drug discovery, patient access, and marketing. From our unique vantage points at Genentech, a leading biotechnology company with a major data science practice, and The Data Incubator, a data-science education company that places and trains data scientists, we have seen how the pharmaceuticals industry has leveraged big data for some potentially revolutionary advances and the challenges it has faced along the way.

{iframe}https://hbr.org/2016/11/the-promise-and-challenge-of-big-data-for-pharma?referral=00563&cm_mmc=email-_-newsletter-_-daily_alert-_-alert_date&utm_source=newsletter_daily_alert&utm_medium=email&utm_campaign=alert_date&spMailingID=16009198&spUserID=MTM4NDQ0NTA1NTkS1&spJobID=904770589&spReportId=OTA0NzcwNTg5S0{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.